Literature DB >> 11678783

Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice.

Z Desta1, K T Kivistö, J J Lilja, J T Backman, N Soukhova, P J Neuvonen, D A Flockhart.   

Abstract

AIMS: To determine whether the pharmacokinetics of cisapride and its interaction with grapefruit juice are stereoselective.
METHODS: The study was a randomized, two-phase cross over design with a washout period of 2 weeks. Ten healthy volunteers were pretreated with either water or 200 ml double strength grapefruit juice three times a day for 2 days. On the 3rd each subject ingested a single 10 mg dose of rac-cisapride tablet. Double strength grapefruit juice (200 ml) or water was administered during cisapride dosing and 0.5 and 1.5 h thereafter. Blood samples were collected before and for 32 h after cisapride administration. Plasma concentrations of cisapride enantiomers were measured by a chiral h.p.l.c. method. A standard 12-lead ECG was recorded before cisapride administration (baseline) and 2, 5, 8, and 12 h later.
RESULTS: This study showed that cisapride pharmacokinetics are stereoselective. In control (water treated) subjects, the mean Cmax (30 +/- 13.6 ng ml-1; P = 0.0008) and AUC(0, infinity) (201 +/- 161 ng ml-1 h; P = 0.029) of (-)-cisapride were significantly higher than the Cmax (10.5 +/- 3.4 ng ml-1) and AUC(0, infinity) (70 +/- 51.5 ng ml-1 h) of (+)-cisapride. There was no marked difference in elimination half-life between (-)-cisapride (4.7 +/- 2.7 h) and (+)-cisapride (4.8 +/- 3 h). Compared with the water treated group, grapefruit juice significantly increased the mean Cmax of (-)-cisapride from 30 +/- 13.6-55.5 +/- 18 ng ml-1 (95% CI on mean difference, -33, -17; P = 0.00005) and of (+)-cisapride from 10.5 +/- 3.4 to 18.4 +/- 6.2 ng ml-1 (95% CI on mean difference, -11.8, -3.9, P = 0.00015). The mean AUC(0, infinity) of (-)-cisapride was increased from 201 +/- 161 to 521.6 +/- 303 ng ml-1 h (95% CI on mean difference, -439, -202; P = 0.0002) and that of (+)-cisapride from 70 +/- 51.5 to 170 +/- 91 ng ml-1 h (95% CI on mean difference, -143, -53; P = 0.0005). The tmax was also significantly increased for both enantiomers (from 1.35 to 2.8 h for (-)-cisapride and from 1.75 to 2.9 h for (+)-cisapride in the control and grapefruit juice group, respectively; P < 0.05). The t(1/2) of (-)-cisapride was significantly increased by grapefruit juice, while this change did not reach significant level for (+)-cisapride. The proportion of pharmacokinetic changes brought about by grapefruit juice was similar for both enantiomers, suggesting non-stereoselective interaction. We found no significant difference in mean QTc intervals between the water and grapefruit juice treated groups.
CONCLUSIONS: The pharmacokinetics of cisapride is stereoselective. Grapefruit juice elevates plasma concentrations of both (-)- and (+)-cisapride, probably through inhibition of CYP3A in the intestine. At present, there are no data on whether the enantiomers exhibit stereoselective pharmacodynamic actions. If they do, determination of plasma concentrations of the individual enantiomers as opposed to those of racemic cisapride may better predict the degree of drug interaction, cardiac safety and prokinetic efficacy of cisapride.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11678783      PMCID: PMC2014582          DOI: 10.1046/j.0306-5251.2001.01473.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  UK licence for cisapride suspended

Authors: 
Journal:  BMJ       Date:  2000-07-29

2.  Tachycardia during cisapride treatment.

Authors:  S Olsson; I R Edwards
Journal:  BMJ       Date:  1992-09-26

3.  Cisapride and fatal arrhythmia.

Authors:  D K Wysowski; J Bacsanyi
Journal:  N Engl J Med       Date:  1996-07-25       Impact factor: 91.245

4.  A comparison of two cohort studies evaluating the safety of cisapride: Prescription-Event Monitoring and a large phase IV study.

Authors:  E Wager; P J Tooley; G L Pearce; L V Wilton; R D Mann
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

5.  Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity.

Authors:  L Q Guo; K Fukuda; T Ohta; Y Yamazoe
Journal:  Drug Metab Dispos       Date:  2000-07       Impact factor: 3.922

6.  Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.

Authors:  Z Desta; N Soukhova; S K Mahal; D A Flockhart
Journal:  Drug Metab Dispos       Date:  2000-07       Impact factor: 3.922

Review 7.  Cisapride. Drug interactions of clinical significance.

Authors:  T A Bedford; D J Rowbotham
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

8.  Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions.

Authors:  H Bohets; K Lavrijsen; J Hendrickx; J van Houdt; V van Genechten; P Verboven; W Meuldermans; J Heykants
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

9.  Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.

Authors:  P C Ho; K Ghose; D Saville; S Wanwimolruk
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

10.  Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: evidence for dominant presystemic elimination at the gut site.

Authors:  T Uno; T Ohkubo; K Sugawara; A Higashiyama; S Motomura; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

View more
  6 in total

1.  Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.

Authors:  Marion Aubert; Rolf Osterwalder; Björn Wagner; Isabelle Parrilla; Icilio Cavero; Lucette Doessegger; Eric A Ertel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies.

Authors:  Mitsuo Saito; Mutsuko Hirata-Koizumi; Mariko Matsumoto; Tsutomu Urano; Ryuichi Hasegawa
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  The effect of grapefruit juice on drug disposition.

Authors:  Michael J Hanley; Paul Cancalon; Wilbur W Widmer; David J Greenblatt
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01-22       Impact factor: 4.481

4.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Effects of Grapefruit and Pomegranate Juices on the Pharmacokinetic Properties of Dapoxetine and Midazolam in Healthy Subjects.

Authors:  Khaled S Abdlekawy; Ahmed M Donia; Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

Review 6.  Medicinal importance of grapefruit juice and its interaction with various drugs.

Authors:  Jawad Kiani; Sardar Z Imam
Journal:  Nutr J       Date:  2007-10-30       Impact factor: 3.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.